EZH2 and diffuse large B-cell lymphoma: To study the impact of EZH2 inhibition on the genome-wide distribution of H3K27me3, we treated two different human cancer cell lines, KARPAS-422 germinal center B-cell like diffuse large B-cell lymphoma and PC9 lung adenocarcinoma, with different EZH2 inhibitors, CPI-360 [18] and GSK126 [23].